End-of-day quote
Taipei Exchange
06:00:00 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
96.9
TWD
|
-0.21%
|
|
+2.65%
|
+13.87%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
3,270
|
2,461
|
3,734
|
7,445
|
9,350
|
-
|
Enterprise Value (EV)
1 |
3,270
|
2,461
|
3,734
|
7,445
|
10,252
|
10,256
|
P/E ratio
|
39.4
x
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
5.23%
|
4.7%
|
5.41%
|
6.56%
|
Capitalization / Revenue
|
-
|
0.96
x
|
1.18
x
|
1.89
x
|
2
x
|
1.75
x
|
EV / Revenue
|
-
|
0.96
x
|
1.18
x
|
1.89
x
|
2.2
x
|
1.92
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
7.4
x
|
6.45
x
|
EV / FCF
|
-
|
16.2
x
|
53.2
x
|
-102
x
|
24.6
x
|
25.6
x
|
FCF Yield
|
-
|
6.19%
|
1.88%
|
-0.98%
|
4.06%
|
3.91%
|
Price to Book
|
-
|
-
|
1.25
x
|
2.13
x
|
2.39
x
|
2.44
x
|
Nbr of stocks (in thousands)
|
88,390
|
78,112
|
78,112
|
87,481
|
96,487
|
-
|
Reference price
2 |
37.00
|
31.50
|
47.80
|
85.10
|
96.90
|
96.90
|
Announcement Date
|
3/29/21
|
3/29/22
|
3/28/23
|
3/21/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
2,571
|
3,169
|
3,930
|
4,664
|
5,341
|
EBITDA
1 |
-
|
-
|
-
|
-
|
1,386
|
1,590
|
EBIT
1 |
-
|
161.4
|
341.6
|
543.3
|
686.3
|
765
|
Operating Margin
|
-
|
6.28%
|
10.78%
|
13.82%
|
14.72%
|
14.32%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
101.8
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
0.9400
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
152.3
|
70.16
|
-72.65
|
416
|
401
|
FCF margin
|
-
|
5.93%
|
2.21%
|
-1.85%
|
8.92%
|
7.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
30.01%
|
25.22%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
2.500
|
4.000
|
5.240
|
6.360
|
Announcement Date
|
3/29/21
|
3/29/22
|
3/28/23
|
3/21/24
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
739.8
|
744
|
928.1
|
933.3
|
934.4
|
1,134
|
1,066
|
1,124
|
1,146
|
1,362
|
EBITDA
1 |
-
|
-
|
-
|
211.4
|
273.5
|
-
|
-
|
338
|
364
|
456
|
EBIT
1 |
60.92
|
71.54
|
101.8
|
114.6
|
171.2
|
155.8
|
124.9
|
167
|
183.5
|
210.5
|
Operating Margin
|
8.24%
|
9.62%
|
10.96%
|
12.28%
|
18.32%
|
13.73%
|
11.72%
|
14.86%
|
16.01%
|
15.46%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/16/22
|
8/15/22
|
5/15/23
|
8/14/23
|
11/14/23
|
3/21/24
|
5/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
902
|
906
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.6508
x
|
0.5698
x
|
Free Cash Flow
1 |
-
|
152
|
70.2
|
-72.7
|
416
|
401
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
11.8%
|
13.2%
|
16%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
6.39%
|
7%
|
8.1%
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
38.30
|
39.90
|
40.60
|
39.70
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
9.780
|
10.20
|
Capex
1 |
-
|
190
|
287
|
506
|
408
|
461
|
Capex / Sales
|
-
|
7.38%
|
9.05%
|
12.89%
|
8.75%
|
8.63%
|
Announcement Date
|
3/29/21
|
3/29/22
|
3/28/23
|
3/21/24
|
-
|
-
|
Last Close Price
96.9
TWD Average target price
126.7
TWD Spread / Average Target +30.72% Consensus |
1st Jan change
|
Capi.
|
---|
| +13.87% | 290M | | -4.68% | 11.09B | | -2.30% | 8.56B | | +44.31% | 5.62B | | -25.51% | 4.41B | | +7.95% | 3.41B | | -14.17% | 2.6B | | -12.74% | 2.07B | | -13.26% | 1.92B | | -28.92% | 1.63B |
Medical Devices & Implants
|